Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Change in Cash (2018 - 2025)

TELA Bio has reported Change in Cash over the past 8 years, most recently at $21.1 million for Q4 2025.

  • Quarterly results put Change in Cash at $21.1 million for Q4 2025, down 40.25% from a year ago — trailing twelve months through Dec 2025 was -$1.8 million (down 130.97% YoY), and the annual figure for FY2025 was -$1.8 million, down 130.97%.
  • Change in Cash for Q4 2025 was $21.1 million at TELA Bio, up from -$5.3 million in the prior quarter.
  • Over the last five years, Change in Cash for TELA hit a ceiling of $35.4 million in Q4 2024 and a floor of -$12.2 million in Q4 2022.
  • Median Change in Cash over the past 5 years was -$8.2 million (2021), compared with a mean of -$1.2 million.
  • Biggest five-year swings in Change in Cash: surged 764.18% in 2023 and later crashed 130.3% in 2024.
  • TELA Bio's Change in Cash stood at -$9.7 million in 2021, then decreased by 25.78% to -$12.2 million in 2022, then increased by 8.18% to -$11.2 million in 2023, then soared by 415.57% to $35.4 million in 2024, then plummeted by 40.25% to $21.1 million in 2025.
  • The last three reported values for Change in Cash were $21.1 million (Q4 2025), -$5.3 million (Q3 2025), and -$7.9 million (Q2 2025) per Business Quant data.